Market overview
The global synthetic clinical trial data market is worth USD 260 mn in 2026 and is forecast to reach USD 1.9 bn by 2036, growing at a 22.0% CAGR. United States is the largest country market and Synthetic control arms and patient data is the largest by data type segment.
| Scope | Artificially generated patient data and virtual control arms used in clinical trial design, analysis and regulatory submissions, sold as software and services to drug and device developers. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 210 mn |
| Value 2026 | USD 260 mn |
| Value 2036 | USD 1.9 bn |
| CAGR 2026-2036 | 22.0% |
| Volume 2026 | 2,232 studies |
| Volume 2036 | 16,304 studies |
| Average price 2026 | USD 116,700 per studie |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Synthetic Clinical Trial Data market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 260 mn |
| 2027 | USD 318 mn |
| 2028 | USD 388 mn |
| 2029 | USD 473 mn |
| 2030 | USD 577 mn |
| 2031 | USD 704 mn |
| 2032 | USD 859 mn |
| 2033 | USD 1.0 bn |
| 2034 | USD 1.3 bn |
| 2035 | USD 1.6 bn |
| 2036 | USD 1.9 bn |
Synthetic Clinical Trial Data market segmentation
By data type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Synthetic control arms and patient data | 40.0% | 40.9% | USD 104 mn | 22.3% |
| Synthetic tabular and health record data | 35.0% | 30.4% | USD 91 mn | 20.3% |
| Synthetic imaging and omics data | 15.0% | 16.6% | USD 39 mn | 23.3% |
| Simulated virtual patients | 10.0% | 12.0% | USD 26 mn | 24.2% |
By end user
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Pharmaceutical and biotechnology | 62.0% | 60.6% | USD 161 mn | 21.7% |
| Contract research organisations | 22.0% | 23.3% | USD 57 mn | 22.7% |
| Medical device companies | 8.0% | 10.0% | USD 21 mn | 24.7% |
| Academic and regulatory | 8.0% | 6.1% | USD 21 mn | 18.7% |
By technique
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Generative AI models | 36.0% | 46.0% | USD 94 mn | 25.0% |
| Statistical simulation | 30.0% | 26.0% | USD 78 mn | 20.3% |
| Rule-based | 18.0% | 12.0% | USD 47 mn | 17.1% |
| Agent-based modelling | 16.0% | 16.0% | USD 42 mn | 22.0% |
By therapeutic area
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oncology | 34.0% | 34.0% | USD 89 mn | 22.0% |
| CNS | 20.0% | 20.0% | USD 52 mn | 22.0% |
| Rare disease | 18.0% | 20.0% | USD 47 mn | 23.3% |
| Cardio and immunology | 28.0% | 26.0% | USD 73 mn | 21.1% |
By delivery
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Cloud licences | 52.0% | 62.0% | USD 135 mn | 24.2% |
| Managed services | 36.0% | 30.0% | USD 94 mn | 19.8% |
| On-premises | 12.0% | 8.0% | USD 31 mn | 17.1% |
Top 25 countries for synthetic clinical trial data by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 93.5% of 2026 revenue and the 25 countries below together hold 97.9%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 135 mn | 52.0% | USD 966 mn | 21.7% |
| 2 | United Kingdom | USD 21 mn | 8.0% | USD 162 mn | 22.7% |
| 3 | Germany | USD 18 mn | 7.0% | USD 129 mn | 21.6% |
| 4 | France | USD 13 mn | 5.0% | USD 93 mn | 21.8% |
| 5 | Switzerland | USD 13 mn | 5.0% | USD 93 mn | 21.8% |
| 6 | Japan | USD 13 mn | 5.0% | USD 86 mn | 20.7% |
| 7 | China | USD 10 mn | 4.0% | USD 110 mn | 26.6% |
| 8 | Canada | USD 7.8 mn | 3.0% | USD 55 mn | 21.6% |
| 9 | Netherlands | USD 6.5 mn | 2.5% | USD 46 mn | 21.5% |
| 10 | Israel | USD 5.2 mn | 2.0% | USD 38 mn | 22.0% |
| 11 | Spain | USD 2.5 mn | 1.0% | USD 17 mn | 20.8% |
| 12 | Italy | USD 1.5 mn | 0.6% | USD 10 mn | 20.9% |
| 13 | India | USD 1.1 mn | 0.4% | USD 11 mn | 25.3% |
| 14 | South Korea | USD 0.91 mn | 0.3% | USD 6.1 mn | 20.9% |
| 15 | Australia | USD 0.76 mn | 0.3% | USD 5.1 mn | 21.1% |
| 16 | Sweden | USD 0.68 mn | 0.3% | USD 4.4 mn | 20.5% |
| 17 | Belgium | USD 0.60 mn | 0.2% | USD 4.0 mn | 20.9% |
| 18 | Denmark | USD 0.55 mn | 0.2% | USD 3.6 mn | 20.8% |
| 19 | Singapore | USD 0.49 mn | 0.2% | USD 4.6 mn | 24.9% |
| 20 | Brazil | USD 0.44 mn | 0.2% | USD 4.4 mn | 25.7% |
| 21 | Ireland | USD 0.42 mn | 0.2% | USD 2.9 mn | 21.2% |
| 22 | Taiwan | USD 0.39 mn | 0.1% | USD 2.7 mn | 21.2% |
| 23 | Poland | USD 0.36 mn | 0.1% | USD 3.6 mn | 25.8% |
| 24 | United Arab Emirates | USD 0.36 mn | 0.1% | USD 3.4 mn | 25.1% |
| 25 | Turkey | USD 0.34 mn | 0.1% | USD 3.2 mn | 25.3% |
| Rest of world | USD 5.4 mn | 2.1% | USD 38 mn | 21.5% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Medidata
- IQVIA
- Certara
- Cytel
Group 2: Regional and specialist players
- Aetion
- MDClone
- Owkin
- Phesi
- TriNetX
- Flatiron Health
Group 3: Emerging and niche players
- Unlearn
- Syntho
- MOSTLY AI
- QuantHealth
- Aitia
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the synthetic clinical trial data market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 22.0% is calculated from the resulting values.
The market is divided by data type, by end user, by technique, by therapeutic area, by delivery. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the synthetic clinical trial data market?
The global synthetic clinical trial data market is estimated at USD 210 mn in 2025 and USD 260 mn in 2026.
How fast will the synthetic clinical trial data market grow?
It is forecast to reach USD 1.9 bn by 2036, a compound annual growth rate of 22.0% from 2026, an increase of USD 1.6 bn.
Which country is the largest market for synthetic clinical trial data?
United States is the largest market by revenue at USD 135 mn in 2026, 52.0% of the global total. The three largest countries together hold 67.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 26.6% a year from 2026 to 2036.
Which synthetic clinical trial data segment is largest?
In the by data type split, Synthetic control arms and patient data is the largest segment with 40.0% of 2026 revenue.
Who are the leading synthetic clinical trial data companies?
Global leaders include Medidata, IQVIA, Certara, Cytel.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- HIV Self-testingUSD 259 mn · 7.5% CAGR
- Dental Oral MicrobiomeUSD 255 mn · 10.0% CAGR
- Automated CPR DeviceUSD 253 mn · 5.5% CAGR
- Augmented Glenoid SystemsUSD 251 mn · 8.5% CAGR
- Dengue VaccinesUSD 247 mn · 22.0% CAGR
- Ascites Fluid Removal DevicesUSD 276 mn · 6.0% CAGR
- Intraoperative Neurophysiological Monitoring ElectrodeUSD 277 mn · 6.5% CAGR
- Medical Device Cyber Risk QuantificationUSD 244 mn · 15.0% CAGR